Ivan joined Inkef after graduating with his MBA from INSEAD. Trained as a biological scientist, he holds a PhD in Genetics and has 10 years of experience in applied and fundamental biological research. His most recent academic role was Marie Sklodowska-Curie actions postdoctoral fellowship at the Institute for Research in Biomedicine (Barcelona), where Ivan studied mechanisms of metastasis in the lab of Roger Gomis. After that, Ivan joined Sanofi’s Eurasian affiliate, where he worked in strategy and business development roles. He has also advised startups in the biotechnology and digital-health space and was an intern at Forbion Capital Partners. Ivan is a person of many hobbies, which include extreme sports, musical instruments and ultrarunning.
I play saxophone. It is a very loud instrument, and when I was studying for my business degree, thin walls of the student housing wouldn’t allow practicing without driving the neighbors mad. My solution was to rehearse deep in the Fontainebleau forest – you should’ve seen the reactions of occasional walkers suddenly spotting a saxophone player in the middle of the woods.
Ambagon Therapeutics applies deep knowledge of the 14-3-3 regulatory protein famiy to create “molecular glues” that stabilize 14-3-3:target complexes. These stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation.
Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, based on proprietary structural insights and the biology of PCSK9, a protein that enables a key step in the control of plasma cholesterol levels.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Its approach of blocking ClC-1 improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Precirix is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. QurAlis scientist are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.
Salvia Bioelectronics is developing a medical device for chronic headaches. The company is working on a new neuromodulation approach, to provide relief for patients who suffer from debilitating migraines more than 15 days per month.